Nootropics Ropinirole Hydrochloride Pharmaceutical powder for Parkinson's Disease Product Name:
4-(2-Di-n-propylaminoethyl)-1,3-dichloro-2H-indol-2-one hydrochloride
CAS: 91374-20-8 Standard: Enterprise Standard Natural / synthetic:
synthetic Level: Pharmaceutical grade Content: 99% Appearance: white
crystal Packing: 25KG/ cardboard drum Area: Early idiopathic Parkinson's
disease Deferred product: Parkinson's drug Application: Acting on
postsynaptic receptors in the striatum, compensating for the deficiency
of dopamine, and compensating for increased sympathetic tone. Ropinirole
can also be used for adjuvant treatment of patients who have already
had switching problems. It can directly act on synaptic receptors, and
it can produce continuous stimulation, thus alleviating the movement
fluctuation of L-dopa, reducing its movement difficulty and reducing the
dosage.
Best Nootropics powder Nootropics Ropinirole Hydrochloride Pharmaceutical powder for
Parkinson's Disease Description: Ropinirole has some of the same effects
as a chemical called dopamine, which occurs naturally in your body. Low
levels of dopamine in the brain are associated with Parkinson's
disease. Ropinirole is used to treat symptoms of Parkinson's disease
(stiffness, tremors, muscle spasms, and poor muscle control). Ropinirole
is also used to treat restless legs syndrome (RLS). Only
immediate-release ropinirole (Requip) is approved to treat either
Parkinson symptoms or RLS. Extended-release ropinirole (Requip XL) is
approved only to treat Parkinson symptoms. Parkinson's and RLS are two
separate disorders. Having one of these conditions will not cause you to
have the other condition.Nootropics Ropinirole Hydrochloride
Pharmaceutical powder for Parkinson's Disease Dosage: The recommended
starting dose for Parkinson's disease is 0.25 mg three times daily.
Based on individual patient therapeutic response and tolerability, if
necessary, the dose should then be titrated with weekly increments as
described in Table 1. After Week 4, if necessary, the daily dose may be
increased by 1.5 mg/day on a weekly basis up to a dose of 9 mg/day, and
then by up to 3 mg/day weekly up to a maximum recommended total daily
dose of 24 mg/day (8 mg three times daily). Doses greater than 24 mg/day
have not been tested in clinical trials.
